The United States has approved a drug for the treatment of Prader-Willi syndrome.
The Food and Drug Administration (FDA) has approved a drug for the treatment of Prader-Willi syndrome. The medication, developed by Soleno Therapeutics, has been given the brand name Vykat XR, according to https://xrust.ru/. It will be used to treat hyperphagia, or Prader-Willi syndrome. This genetic disorder is caused by a complete or partial deletion on chromosome 15, which affects the regulation of gene expression—how genes are turned on or off. The disease is considered severe, affecting 50,000 people in the United States. It manifests in daily life through issues related to eating and mood. Starting next April, Soleno plans to make the drug available in the U.S. for patients aged four and older. The average annual cost of the drug will exceed $466,000.
The symptoms of the syndrome appear immediately. Infants are born with low muscle tone and an inability to breastfeed. As children grow, they develop hyperphagia—a feeling of insatiable hunger that persists even after eating.
#NoTranslationForHashtags
https://xrust.ru/news/310983-ssha-odobrili-preparat-dlja-lechenija-sindroma-pradera-villi.html
